Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Novel ester of sPLA2 inhibitor has improved oral bioavailability

Nov. 23, 2000

Irbesartan to be evaluated in clinical trial for new indication: heart failure

Nov. 23, 2000

Oral bosentan effective as pulmonary hypertension therapy

Nov. 23, 2000

Initial phase I results show good safety for Antrin photoangioplasty

Nov. 23, 2000

COPERNICUS results show good efficacy for carvedilol in severe HF

Nov. 22, 2000

Phase III results reported for Natrecor in CHF

Nov. 22, 2000

Val-HeFT results reported at AHA sessions

Nov. 22, 2000

FDA approves Boehringer Ingelheim's Micardis HCT

Nov. 21, 2000

PGE1 derivatives from Taisho and use in cardiovascular disorders

Nov. 21, 2000

CB1 cannabinoid receptor activation involved in cirrhosis-associated hypotension

Nov. 21, 2000

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...